Fil LTD Tg Therapeutics, Inc. Transaction History

Fil LTD

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$13.32 - $19.19 $45,381 - $65,380	3,407 Added 7.33%	49,907 $887,000
Q1 2024 May 13, 2024	BUY	$13.02 - $21.3 $42,627 - $69,736	3,274 Added 7.57%	46,500 $707,000
Q4 2023 Feb 13, 2024	BUY	$6.68 - $18.81 $288,749 - $813,081	43,226 New	43,226 $738,000
Q2 2023 Aug 11, 2023	BUY	$15.48 - $35.0 $83,205 - $188,125	5,375 Added 4.93%	114,412 $2.84 Million
Q1 2023 May 11, 2023	BUY	$10.23 - $19.34 $1.12 Million - $2.11 Million	109,037 New	109,037 $1.64 Million
Q4 2021 Feb 14, 2022	SELL	$15.2 - $35.51 $2.59 Million - $6.06 Million	-170,707 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$21.78 - $40.45 $144,967 - $269,235	-6,656 Reduced 3.75%	170,707 $5.68 Million
Q2 2021 Aug 13, 2021	BUY	$32.5 - $48.96 $1.07 Million - $1.61 Million	32,842 Added 22.72%	177,363 $6.88 Million
Q1 2021 May 14, 2021	BUY	$41.61 - $54.3 $6.01 Million - $7.85 Million	144,521 New	144,521 $6.97 Million

345

87.6M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.86B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Fil LTD, based on Form 13F filings with the SEC.

Stay updated on Fil LTD with notifications on news.